David Loew, Ipsen CEO

Ipsen's pan­cre­at­ic can­cer drug bests decade-old stan­dard of care

Ipsen’s can­cer drug Onivyde, when com­bined with chemother­a­py, per­formed bet­ter than stan­dard of care at ex­tend­ing the lives of pa­tients with a cer­tain pan­cre­at­ic can­cer.

The bio­phar­ma said the tri­al re­sults mark the first time an in­ves­ti­ga­tion­al drug has shown bet­ter over­all sur­vival and pro­gres­sion-free sur­vival as a first-line treat­ment than stan­dard of care for pa­tients with metasta­t­ic pan­cre­at­ic duc­tal ade­no­car­ci­no­ma (mP­DAC). This year, about 64,000 peo­ple in the US will be di­ag­nosed with pan­cre­at­ic can­cer, which has the worst five-year sur­vival rate, ac­cord­ing to the Amer­i­can Can­cer So­ci­ety.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA